AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32063035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound applied in the first and second months (Group III)
Number of subjects: 100
Study 32063035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound applied in the first month (Group II)
Number of subjects: 100
Study 32063035 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous ultrasound applied in the first month (Group I)
Number of subjects: 100
Study 32063035 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed ultrasound applied in the first and second months (Group IV)
Number of subjects: 100
Study 32063035 — intervention group
Group type: COMPARATOR
Intervention: Exercise sessions only for eight weeks (Group V)
Number of subjects: 100
Study 35712941 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group (acupuncture at sphenopalatine ganglion + conventional acupuncture)
Number of subjects: 180
Study 35712941 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (conventional acupuncture)
Number of subjects: 180
Study 35712941 — intervention group
Group type: COMPARATOR
Intervention: Sphenopalatine ganglion group
Number of subjects: 180
Study 33639508 — intervention group
Group type: EXPERIMENTAL
Intervention: LC@I‐PANi nanoparticles
Number of subjects: 0
Study 32758135 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral psychotherapy tailored to the specific needs of the population, provided by residential psychotherapists as part of the regular healthcare service.
Number of subjects: 130
Study 32758135 — intervention group
Group type: COMPARATOR
Intervention: Individual psychosocial telephone counselling and a self-help guide (active control group).
Number of subjects: 130
Study 36378768 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (Strong Hearts, Healthy Communities-2.0 program)
Number of subjects: 182
Study 32399201 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message
Number of subjects: 403
Study 32399201 — intervention group
Group type: COMPARATOR
Intervention: Standard text message
Number of subjects: 403
Study 32639293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin, n = 6
Number of subjects: 13
Study 32639293 — intervention group
Group type: COMPARATOR
Intervention: Placebo, n = 7
Number of subjects: 13
Study 35218248 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft plus a collagen membrane
Number of subjects: 24
Study 35218248 — intervention group
Group type: EXPERIMENTAL
Intervention: Allograft plus a collagen membrane
Number of subjects: 24
Study 33405291 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (triggered by hemoglobin ≤8 g/dL)
Number of subjects: 630
Study 33405291 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (triggered by hemoglobin ≤10 g/dL)
Number of subjects: 630
Study 33405291 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 630
Study 33405291 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 630
Study 35556167 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture with cyanoacrylate skin adhesive
Number of subjects: 834
Study 35556167 — intervention group
Group type: COMPARATOR
Intervention: Stapled skin closure (historical control group)
Number of subjects: 834
Study 34659110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulening metformin SR tablets (n=446)
Number of subjects: 886
Study 34659110 — intervention group
Group type: COMPARATOR
Intervention: Glucophage metformin tablets (n=440)
Number of subjects: 886
Study 34708917 — intervention group
Group type: EXPERIMENTAL
Intervention: Difelikefalin (5 and 15 mcg/kg)
Number of subjects: 44
Study 34708917 — intervention group
Group type: COMPARATOR
Intervention: Pentazocine (0.5 mg/kg)
Number of subjects: 44
Study 34708917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 35852035 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooled dialysate (35.5°C)
Number of subjects: 45
Study 35852035 — intervention group
Group type: COMPARATOR
Intervention: Routine dialysate (36.5°C)
Number of subjects: 45
Study 33211251 — intervention group
Group type: EXPERIMENTAL
Intervention: qCON (Conox) during desflurane anesthesia
Number of subjects: 22
Study 33211251 — intervention group
Group type: EXPERIMENTAL
Intervention: PSI (Sedline) during desflurane anesthesia
Number of subjects: 22
Study 33211251 — intervention group
Group type: COMPARATOR
Intervention: qCON and PSI during sevoflurane-propofol anesthesia (Control)
Number of subjects: 22
Study 34936072 — intervention group
Group type: EXPERIMENTAL
Intervention: trans‐SAP PETLD
Number of subjects: 98
Study 34936072 — intervention group
Group type: COMPARATOR
Intervention: conventional PETLD
Number of subjects: 98
Study 33109138 — intervention group
Group type: EXPERIMENTAL
Intervention: Information only group
Number of subjects: 720
Study 33109138 — intervention group
Group type: EXPERIMENTAL
Intervention: Information plus home delivery group
Number of subjects: 720
Study 33109138 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 720
Study 33109138 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 720
Study 35135037 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 55
Study 35135037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 33388858 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids 500 mg/day
Number of subjects: 0
Study 33388858 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids 1000 mg/day
Number of subjects: 0
Study 33388858 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids (both dosages)
Number of subjects: 0
Study 34415561 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 25 mg Omecamtiv mecarbil (OM)
Number of subjects: 86
Study 34415561 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 50 mg Omecamtiv mecarbil (OM)
Number of subjects: 86
Study 34415561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 25 mg Omecamtiv mecarbil (OM)
Number of subjects: 86
Study 34415561 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple oral doses of 37.5 mg or 50 mg Omecamtiv mecarbil (OM)
Number of subjects: 86
Study 32605806 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab 140 mg every 2 weeks
Number of subjects: 186
Study 35065057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab monotherapy (240 mg every 2 weeks for up to three doses before surgery, then 480 mg every 4 weeks for 2 years)
Number of subjects: 30
Study 35065057 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab (240 mg nivolumab every 2 weeks plus 1 mg/kg ipilimumab concurrently with the first preoperative dose, then 480 mg nivolumab every 4 weeks for 2 years plus 1 mg/kg ipilimumab every 6 weeks for up to four cycles)
Number of subjects: 30
Study 35473780 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1 blockade (IL-1 blockade)
Number of subjects: 0
Study 32970970 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC) 4x/week for 12 weeks
Number of subjects: 24
Study 32970970 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling (PC) 4x/week for 12 weeks
Number of subjects: 24
Study 32970970 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC)
Number of subjects: 24
Study 32970970 — intervention group
Group type: COMPARATOR
Intervention: Passive cycling (PC)
Number of subjects: 24
Study 32970970 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation–assisted cycling (FESC) and Passive cycling (PC)
Number of subjects: 24
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 0% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 5% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 10% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 15% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 20% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 25% error
Number of subjects: 0
Study 33491205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcer delivery with 50% error
Number of subjects: 0
Study 32827517 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ropinirole
Number of subjects: 0
Study 32827517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34521264 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IUs of ergocalciferol monthly after bariatric surgery
Number of subjects: 32
Study 34521264 — intervention group
Group type: COMPARATOR
Intervention: Standard level vitamin D supplement after bariatric surgery
Number of subjects: 32
Study 32433198 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cohort (223 patients) using the PRoFiT-NU Score for predicting functional outcomes.
Number of subjects: 328
Study 32433198 — intervention group
Group type: COMPARATOR
Intervention: Validation cohort (105 patients) using the PRoFiT-NU Score for predicting functional outcomes.
Number of subjects: 328
Study 34192426 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine (5-μg doses, 2 doses administered 21 days apart)
Number of subjects: 15187
Study 34192426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15187
Study 34192426 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2373 vaccine
Number of subjects: 15187
Study 34192426 — intervention group
Group type: COMPARATOR
Intervention: NVX-CoV2373 vaccine and placebo
Number of subjects: 15187
Study 32919280 — intervention group
Group type: EXPERIMENTAL
Intervention: CER-001 (8 mg/kg, intravenous infusions, 9 weekly infusions followed by infusions every two weeks)
Number of subjects: 30
Study 32919280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34525100 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated encouragement messages via e-mail and SMS before exams
Number of subjects: 0
Study 34525100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no encouragement messages)
Number of subjects: 0
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 30 ng/mL in AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 20 ng/mL in AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 10 ng/mL in AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 30 ng/mL in male AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 20 ng/mL in male AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D levels < 10 ng/mL in male AS patients
Number of subjects: 919
Study 32414130 — intervention group
Group type: COMPARATOR
Intervention: Inadequate levels of vitamin D among controls
Number of subjects: 919
Study 32374239 — intervention group
Group type: EXPERIMENTAL
Intervention: Local TXA
Number of subjects: 168
Study 32374239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic+short infusion TXA
Number of subjects: 168
Study 32374239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic+long infusion TXA
Number of subjects: 168
Study 32374239 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic+oral TXA
Number of subjects: 168
Study 32374239 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 168
Study 34582653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril and Bisoprolol
Number of subjects: 74
Study 34582653 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 74
Study 32312606 — intervention group
Group type: EXPERIMENTAL
Intervention: Classification-specific treatment (exercise to control or prevent lumbopelvic motion during lower-extremity movement)
Number of subjects: 39
Study 32312606 — intervention group
Group type: COMPARATOR
Intervention: General exercises and education about LBP (control group)
Number of subjects: 39
Study 35894088 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise inducing ischemic leg symptoms
Number of subjects: 264
Study 35894088 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise without ischemic leg symptoms
Number of subjects: 264
Study 35894088 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group
Number of subjects: 264
Study 34018987 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylated spirit
Number of subjects: 323
Study 34018987 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine gel
Number of subjects: 323
Study 35997992 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 54
Study 35997992 — intervention group
Group type: COMPARATOR
Intervention: General Physical Education (PE)
Number of subjects: 54
Study 35997992 — intervention group
Group type: COMPARATOR
Intervention: Passive Controls
Number of subjects: 54
Study 34864925 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ) 120/960mg
Number of subjects: 748
Study 34864925 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) 1500/75mg
Number of subjects: 748
Study 35184905 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors (PRGF)
Number of subjects: 74
Study 35184905 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRGF)
Number of subjects: 74
Study 33740977 — intervention group
Group type: COMPARATOR
Intervention: Opioid analgesia alone (standard treatment)
Number of subjects: 62
Study 33740977 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal analgesia (Pregabalin, Acetaminophen, Naproxen, and opioids if required)
Number of subjects: 62
Study 35419729 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture with moxibustion at 37 °C
Number of subjects: 63
Study 33834177 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid for two days only (n=17)
Number of subjects: 69
Study 33834177 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid for two days followed by moxifloxacin (n=16)
Number of subjects: 69
Study 33834177 — intervention group
Group type: EXPERIMENTAL
Intervention: No isoniazid (n=18)
Number of subjects: 69
Study 33834177 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (isoniazid for all 14 days, n=18)
Number of subjects: 69
Study 35576286 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia with 12 ml of 0.25% bupivacaine and 1% lignocaine plain (Group T)
Number of subjects: 82
Study 35576286 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Group G)
Number of subjects: 82
Study 35576286 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural anaesthesia (Group T)
Number of subjects: 82
Study 35467903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritize one behavior
Number of subjects: 1802
Study 35467903 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritize two behaviors
Number of subjects: 1802
Study 35467903 — intervention group
Group type: COMPARATOR
Intervention: No prioritization (control)
Number of subjects: 1802
Study 33940347 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks or 400 mg every 6 weeks by intravenous infusion)
Number of subjects: 0
Study 33940347 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC: FOLFOX6/FOLFIRI alone or in combination with bevacizumab/cetuximab)
Number of subjects: 0
Study 34082792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurveda interventions including Agastya Haritaki 6g and Ashwagandha tablet 500mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days.
Number of subjects: 110
Study 34082792 — intervention group
Group type: COMPARATOR
Intervention: WHO Rehabilitation Self‐Management after COVID‐19 related illness for 90 days.
Number of subjects: 110
Study 34082792 — intervention group
Group type: EXPERIMENTAL
Intervention: Ayurveda interventions
Number of subjects: 110
Study 32804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 226
Study 32804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 226
Study 32804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking
Number of subjects: 226
Study 32804876 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact
Number of subjects: 226
Study 32804876 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pain intervention)
Number of subjects: 226
Study 36127739 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled aviptadil (67 μg, three times a day for 10 days)
Number of subjects: 132
Study 36127739 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (three times a day for 10 days)
Number of subjects: 132
Study 34023841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Guided Surgery (DGS)
Number of subjects: 22
Study 34023841 — intervention group
Group type: COMPARATOR
Intervention: Static Guided Surgery (SGS)
Number of subjects: 22
Study 36345809 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib and letrozole
Number of subjects: 3836
Study 36345809 — intervention group
Group type: COMPARATOR
Intervention: Letrozole only
Number of subjects: 3836
Study 33965734 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 33965734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33965734 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram and Placebo (combined)
Number of subjects: 0
Study 32847900 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal splint and mouth-breathing training (P-group) before surgery
Number of subjects: 200
Study 32847900 — intervention group
Group type: COMPARATOR
Intervention: No intervention (C-group)
Number of subjects: 200
Study 35463514 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Number of subjects: 111
Study 35463514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 36425919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive ultrasound-guided single-shot lateral sciatic nerve block with 20 ml of 0.75% ropivacaine
Number of subjects: 30
Study 36425919 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 30
Study 32698622 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive nostalgia
Number of subjects: 366
Study 32698622 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative nostalgia
Number of subjects: 366
Study 32698622 — intervention group
Group type: EXPERIMENTAL
Intervention: Coactive nostalgia
Number of subjects: 366
Study 34560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Distribution of HIV self-test kits
Number of subjects: 505
Study 34560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving HIV self-test kits
Number of subjects: 505
Study 34560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever having heard about HIV self-testing
Number of subjects: 505
Study 34560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to self-test for HIV in front of a sexual partner
Number of subjects: 505
Study 34560878 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to peer-led HIV self-testing education and promotion
Number of subjects: 505
Study 32220099 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Number of subjects: 154
Study 32220099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain relief
Number of subjects: 154
Study 32220099 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain improvement
Number of subjects: 154
Study 36130612 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery denervation
Number of subjects: 535
Study 36130612 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 535
Study 36130612 — intervention group
Group type: COMPARATOR
Intervention: Crossover group
Number of subjects: 535
Study 36130612 — intervention group
Group type: COMPARATOR
Intervention: Non-crossover group
Number of subjects: 535
Study 32763109 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg, paclitaxel 175 mg/m(2), and carboplatin AUC 5; median bevacizumab duration was 6.7 months; 57% received maintenance bevacizumab.
Number of subjects: 150
Study 36369645 — intervention group
Group type: EXPERIMENTAL
Intervention: MRx1234
Number of subjects: 366
Study 36369645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 366
Study 33345659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oncokompas (intervention group, n=320)
Number of subjects: 625
Study 33345659 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 months waiting list, n=305)
Number of subjects: 625
Study 32291162 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood Stress Score (NSS) decile
Number of subjects: 0
Study 32291162 — intervention group
Group type: COMPARATOR
Intervention: Area Deprivation Index (ADI) decile
Number of subjects: 0
Study 35468766 — intervention group
Group type: EXPERIMENTAL
Intervention: botulinum toxin‐A plus 3 months of evidence‐based movement training
Number of subjects: 140
Study 35468766 — intervention group
Group type: COMPARATOR
Intervention: botulinum toxin‐A plus a handout of exercises
Number of subjects: 140
Study 32150521 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive 72-hour short-term antibiotic strategy
Number of subjects: 0
Study 32150521 — intervention group
Group type: COMPARATOR
Intervention: Standard antibiotic usage
Number of subjects: 0
Study 32150521 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive antibiotic strategy
Number of subjects: 0
Study 35575766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.5 MAC
Number of subjects: 80
Study 35575766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane at 0.75 MAC
Number of subjects: 80